Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Ranks among the top 15% companies globally
The company received 1 (One) observation in the Form-483
Dilip Shanghvi to continue as the Executive Chairman of the Board
Subscribe To Our Newsletter & Stay Updated